pment pathways in other industrialized countries; that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; or that third parties on whom we depend will perform as anticipated.
Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2012 Cardium Therapeutics, Inc. All rights reserved.
Cardium Therapeutics®, Generx®, Cardionovo™, Tissue Repair™, Gene ActiPage: 1 2 3 4 5 6 7 8 Related biology technology :1
. Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardiums New Catheter-Based Method Significantly Boosts Gene Delivery To The Heart2
. Cardium Presents First Quarter 2012 Financial Results and Recent Developments3
. Cardium to Present at Upcoming Investor Conferences4
. CryoLife Announces Quarterly Cash Dividend for the Fourth Quarter 20125
. MedCath Announces Extension of Tolling Agreement With U.S. Department of Justice6
. Cord Blood America Announces 3rd Quarter and Nine Months 2012 Financial Results7
. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London8
. Egenix, Inc. Announces New Director, John Reid9
. The Trendlines Group Announces Co-development Agreement with Endo10
. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue11
. Sapio Sciences Announces Exemplar LIMS for Tablet Computers